Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting

References

• World Health Organization. Schizophrenia: Fact sheet #397. 2014. Available at: http://www.who.int/mediacentre/factsheets/ [Last accessed 20 March 2017]
   Google Scholar
• Murray CJ, Lopez AD; The World Health Organization; World Bank; Harvard School of Public Health. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020: Summary. Geneva: World Health Organization, 1996
   Google Scholar
• Cloutier M, Sanon Aigbogun M, Guerin A, et al. The Economic Burden of Schizophrenia in the United States in 2013. J Clin Psychiatry 2016;77:764-71
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al. Steering Committee on Practice Guidelines: practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(2 Suppl):1-56
   PubMed Web of Science ®Google Scholar
• Kane JM. Treatment adherence and long-term outcomes. CNS Spectr 2007;12(Suppl 17):21-6
   PubMed Web of Science ®Google Scholar
• Kane JM. Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry 2007;68(Suppl 14):27-30
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al. Practice Guideline for the Treatment of Patients with Schizophrenia, Second Edition. 2004. Available at: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/schizophrenia.pdf. [Last accessed 28 June 2017]
   Google Scholar
• Thieda P, Beard S, Richter A, Kane J. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003;54:508-16
   PubMed Web of Science ®Google Scholar
• Cooper D, Moisan J, Grégoire J-P. Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J Clin Psychiatry 2007;68:818-25
   PubMed Web of Science ®Google Scholar
• Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909
   PubMed Web of Science ®Google Scholar
• Masand PS, Roca M, Turner MS, Kane JM. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry 2009;11:147-54
   PubMedGoogle Scholar
• Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 2006;67(Suppl5):3-8
   Web of Science ®Google Scholar
• Knapp M, King D, Pugner K, Lapuerta P. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry 2004;184:509-16
   PubMed Web of Science ®Google Scholar
• Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007;23:2305-12
   PubMed Web of Science ®Google Scholar
• Olivares JM, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287-96
   PubMed Web of Science ®Google Scholar
• Panish J, Karve S, Candrilli SD, Dirani R. Association between adherence to and persistence with atypical antipsychotics and psychiatric relapse among US Medicaid-enrolled patients with schizophrenia. J Pharm Heal Serv Res 2013;4:29-39
   Google Scholar
• Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009;15:e22-33
   PubMed Web of Science ®Google Scholar
• Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure–lowering medication in ambulatory care? Arch Intern Med 2004;164:722
   PubMed Web of Science ®Google Scholar
• Medic G, Higashi K, Littlewood KJ, et al. Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis. Neuropsychiatr Dis Treat 2013;9:119-31
   PubMed Web of Science ®Google Scholar
• Diaz E, Neuse E, Sullivan MC, et al. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 2004;65:354-60
   PubMed Web of Science ®Google Scholar
• Pilon D, Joshi K, Tandon N, et al. Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic. Patient Prefer Adherence 2017; 11:619-29
   PubMed Web of Science ®Google Scholar
• Lafeuille M-H, Frois C, Cloutier M, et al. Factors associated with adherence to the HEDIS quality measure in Medicaid patients with schizophrenia. Am Heal Drug Benefits 2016;9:399-410
   PubMed Web of Science ®Google Scholar
• Marcus SC, Zummo J, Pettit AR, et al. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm 2015;21:754-68
   PubMed Web of Science ®Google Scholar
• Rainer M. Risperidone long-acting injection: a review of its long term safety and efficacy. Neuropsych Dis Treat 2008;4(5):919-27
   PubMedGoogle Scholar
• Paliperidone palmitate (Invega Sustenna). Available at: http://www.janssencns.com/invegasustenna/ [Last accessed 4 April 2016]
   Google Scholar
• Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry 2015;76:554-61
   PubMed Web of Science ®Google Scholar
• Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010;116:107-117
   PubMed Web of Science ®Google Scholar
• Joshi K, Lin J, Lingohr-Smith M, Fu DJ. Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder. J Med Econ 2015;18(8):629-36
   PubMed Web of Science ®Google Scholar
• Schreiner A, Aadamsoo K, Altamura AC, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res 2015;169(1-3):393-9
   PubMed Web of Science ®Google Scholar
• Fu D-J, Turkoz I, Simonson RB, et al. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. J Clin Psychiatry 2015;76:253-62
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals Inc. Invega Trinza (paliperidone palmitate) extended-release injectable suspension US prescribing information. Available at: http://www.janssencns.com/shared/product/invegatrinza/prescribing-information.pdf [Last accessed 27 June 2017]
   Google Scholar
• Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia. JAMA Psychiatry 2015;8560:1-10
   Google Scholar
• Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. Int J Neuropsychopharmacol 2016;19(7):1-14
   Web of Science ®Google Scholar
• Xiao Y, Muser E, Lafeuille M-H, et al. Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patients. J Comp Eff Res 2015;4:579-92
   PubMed Web of Science ®Google Scholar
• Dilla T, Ciudad A, Álvarez M. Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia. Patient Prefer Adherence 2013;7:275
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Kim E, Bermak J, et al. Does half-life matter after antipsychotic discontinuation? A relapse comparison in schizophrenia with 3 different formulations of paliperidone. J Clin Psychiatry 2017;June 20, DOI: 10.4088/JCP.16m11308 (Epub ahead of print)
   Web of Science ®Google Scholar
• Lafeuille M-H, Grittner AM, Fortier J, et al. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics. Am J Heal Pharm 2015;72:378-89
   PubMed Web of Science ®Google Scholar
• Baser O, Xie L, Pesa J, Durkin M. Healthcare utilization and costs of veterans health administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. J Med Econ 2015;18:357-65
   PubMed Web of Science ®Google Scholar
• Pesa JA, Doshi D, Wang L, et al. Health care resource utilization and costs of California Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment. Curr Med Res Opin 2017;33:723-31
   PubMed Web of Science ®Google Scholar